肠道微生物群衍生生物活性化合物的分子机制和临床应用在与代谢功能障碍相关的脂肪肝疾病中
Chengyun Ma1, Jing Wang1, Xuanli Song2
1Department of Clinical Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Frontiers in immunology
|November 5, 2025
概括
与代谢 (功能障碍) 相关的脂肪肝疾病 (MAFLD) 与肠道微生物有关. 微生物化合物影响MAFLD,提供诊断和治疗点.
科学领域:
- 胃肠病学和肝病学 胃肠学和肝病学
- 微生物学 微生物学
- 代谢疾病 代谢疾病
背景情况:
- 与代谢 (功能障碍) 相关的脂肪肝疾病 (MAFLD) 是一个日益严重的全球健康问题.
- MAFLD的致病性涉及肠道微生物群失调和代谢中断.
- 肠道微生物代谢物极大地影响MAFLD的进展.
研究的目的:
- 审查由肠道微生物群衍生的生物活性化合物影响MAFLD发展的机制.
- 探索MAFLD中微生物代谢物概况的诊断潜力.
- 突出针对MAFLD的微生物向治疗策略.
主要方法:
- 分子机制的系统审查.
- 在MAFLD中分析肠道微生物代谢物.
- 对诊断和治疗策略的评估.
主要成果:
- 肠道微生物代谢物 (SCFA,胆汁酸,类衍生物,EVs) 调节MAFLD中的肝脂代谢,炎症和表观遗传学.
- 独特的代谢物概况为MAFLD差异诊断提供了潜在的可能性.
- 针对微生物群的治疗方法在MAFLD管理方面表现有前途.
结论:
- 了解肠道微生物群与宿主的代谢相互作用是MAFLD病变的关键.
- 来自微生物群的化合物对MAFLD的发展和进展至关重要.
- 准肠道微生物群为MAFLD提供了新的诊断和治疗途径.
相关概念视频
Overview of Fatty Acid Metabolism
36.3K
Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
36.3K
Lipid Catabolism
838
Triglycerides serve as crucial long-term energy storage molecules in microorganisms, providing a dense source of metabolic energy. Their breakdown is mediated by lipases, which hydrolyze triglycerides into glycerol and free fatty acids. Each of these components follows distinct metabolic pathways, ultimately contributing to ATP synthesis and cellular energy homeostasis.Glycerol MetabolismGlycerol, released from triglyceride hydrolysis, is phosphorylated by glycerol kinase to form...
838
Overview of Lipid Metabolism
4.8K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
4.8K
Bacterial Flora of the Large Intestine
1.5K
The gut microbiome is formed by a vast and diverse community of bacteria that colonizes our large intestine. These bacteria start residing in the gut from birth and continue diversifying throughout life, influenced by factors such as diet, lifestyle, and stress. The gut bacterial community also includes bacteria from food and those that enter the colon through the anus.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
1.5K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
164
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
164
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
188
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
188


